CJC-1295 DAC half life is roughly 6 to 8 days, far longer than the modified GRF(1-29) without DAC. Learn how the half life shapes dosing and research design.
The CJC-1295 DAC half-life is roughly 6 to 8 days in published pharmacokinetic research, which makes it one of the longest-acting growth hormone-releasing hormone analogs studied. The extended window comes from a drug affinity complex (DAC) that binds the peptide to albumin in the bloodstream. In practical terms, one injection stays active for a week or more instead of fading within minutes.
What Is CJC-1295 DAC?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC form adds a maleimidopropionic acid group that attaches to circulating albumin, and that attachment is the reason the peptide clears so slowly.
The version without DAC, often labeled Mod GRF(1-29), keeps the same core sequence but lacks the albumin-binding tag. That single difference separates a once-weekly research compound from one that is typically dosed several times a day.
CJC-1295 DAC is not FDA-approved for human use in the United States. It is sold as a research chemical, and no regulator has reviewed it for safety, purity, or effectiveness in people.
How Long Is the CJC-1295 DAC Half-Life?
Albumin binding explains almost everything about the half-life. Once the peptide is bound to albumin, the kidneys cannot filter it out quickly, so it circulates for days rather than minutes.
Most published reports place the CJC-1295 DAC half-life at about 6 to 8 days. Differences in that number usually reflect assay methods, dose size, and whether researchers measured total or unbound peptide.
By contrast, the cjc 1295 no dac half-life is measured in minutes, not days. That gap is the single most important practical difference between the two compounds.
| Feature | CJC-1295 DAC | CJC-1295 No DAC (Mod GRF 1-29) |
|---|---|---|
| Reported half-life | About 6 to 8 days | About 30 minutes |
| Albumin binding | Yes, through the DAC group | No |
| Research injection frequency | Every 5 to 7 days | 1 to 3 times daily |
| Typical research dose | 1 to 2 mg per week | 100 to 300 mcg per dose |
| Common vial sizes | 5 mg and 10 mg | 2 mg and 5 mg |
| Typical study goal | Sustained exposure | Pulsatile release |
Why the Half-Life Shapes Dosing Strategy
A long half-life means fewer injections, but it also means a dose cannot be adjusted or withdrawn quickly. If someone experiences side effects, the compound keeps working for days after the last injection.
Most research protocols list a cjc-1295 with dac dosage of roughly 1 to 2 mg per week, given as one injection or split into two. That schedule is only possible because of the extended half-life.
Shorter-acting peptides work differently. A cjc-1295 no dac dosage is usually in the 100 to 300 mcg range, injected two or three times daily to mimic the body's natural pulsatile release.
A longer half-life does not make a peptide safer; it only makes the exposure window longer.
CJC-1295 DAC vs No DAC: Key Differences
A side-by-side look at cjc-1295 dac vs no dac comes down to convenience versus control. The DAC version produces a steady, elevated level of the peptide, while the no-DAC version produces sharp peaks that fade quickly.
Researchers studying natural growth hormone pulses usually prefer the short-acting form because it better mimics physiology. Researchers studying sustained exposure tend to choose the DAC version.
Community threads often compare the short-acting peptide with ipamorelin, a ghrelin-receptor agonist that triggers its own pulse. Blending two short-acting compounds is a very different strategy from using one long-acting peptide.
Safety, Legality, and Sourcing Reality
CJC-1295 DAC has not been approved by the FDA for any human indication. Injecting an unapproved peptide carries risks that include allergic reactions, injection-site problems, and unknown long-term effects on hormone regulation.
Growth-hormone-related compounds can also affect blood sugar, fluid retention, and joint comfort. Anyone considering use should talk with a licensed healthcare professional instead of relying on forum anecdotes.
Listings that advertise cjc 1295 dac for sale rarely include independent purity testing or a full certificate of analysis. Vials labeled 5 mg or 10 mg may contain less peptide than stated, or a different compound entirely.
- Third-party testing confirms identity and purity, not safety in humans.
- Cold-chain shipping protects peptide integrity during transit.
- A contaminated batch means a full week of exposure, not a few hours.
Because the half-life is so long, unwanted effects from CJC-1295 DAC may persist for days after the last dose.
Key Takeaways on the CJC-1295 DAC Half-Life
The extended half-life of about 6 to 8 days is what separates CJC-1295 DAC from nearly every other GHRH analog on the research market. That one property drives weekly dosing schedules, longer washout periods, and a slower return to baseline.
Anyone comparing peptides should weigh convenience against control and treat unapproved research chemicals with appropriate caution. Speaking with a healthcare professional is the responsible first step before considering any use.
Frequently Asked Questions
How long does CJC-1295 DAC stay in your system?
Published research reports a half-life of about 6 to 8 days, so a single dose stays active for well over a week. Using standard pharmacokinetic estimates of four to five half-lives for near-complete clearance, trace amounts could remain for several weeks. Individual clearance varies with dose, body composition, and overall health.
Is CJC-1295 DAC the same as CJC-1295 without DAC?
No. CJC-1295 with DAC carries an albumin-binding group that extends its half-life to roughly 6 to 8 days, while the version without DAC clears in about 30 minutes. The two compounds share a core sequence but behave very differently in the body, which is why their dosing schedules are not interchangeable.
Can you buy CJC-1295 DAC legally in the US?
CJC-1295 DAC is not FDA-approved for human use, so it cannot legally be sold as a medication or dietary supplement. It is typically marketed as a research chemical, and legality depends on state law and how the product is labeled and sold. Unapproved products are not held to the same purity or safety standards as approved drugs.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.